Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-c3 and Gemcitabine in Second-Line Advanced Pancreatic Cancer
NCT06015659Phase 2Terminated
- Start
- Nov 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azenosertib in pancreatic adenocarcinoma (PDAC). Started Nov 2023; status: terminated.
02
Drugs
azenosertib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06015659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015659.